Compare DexCom, Inc. (DXCM) vs iShares 7-10 Year Treasury Bond ETF (IEF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs iShares 7-10 Year Treasury Bond ETF — how do they compare? DexCom, Inc. trades at $83.92 (market cap $31.86B), while iShares 7-10 Year Treasury Bond ETF trades at $89.28 (market cap $41.13B). The key difference: iShares 7-10 Year Treasury Bond ETF is the larger of the two by market cap, and DexCom, Inc. is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and iShares 7-10 Year Treasury Bond ETF for 108 Days on average.
| DXCM | IEF | |
|---|---|---|
Market Cap | $31.86B | $41.13B |
Volume | 3,607,070 | 10,340,382 |
Sector | Health | Fixed Income |
52-Week High | $92.34 | $97.99 |
52-Week Low | $54.84 | $88.92 |
Typical Hold Time | 62 Days | 108 Days |
Enterprise Value | $31.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
IEF trades at $89.295 with a modest 0.21% daily gain amid a challenging bond market environment. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. Recent Treasury yield volatility and bond market selloffs have created headwinds for fixed income ETFs, while dividend distributions continue with recent payouts around $0.31-0.33 per share.
The outlook remains cautious as rising Treasury yields and inflation concerns pressure bond ETFs. While current yields provide income appeal, further rate increases could depress prices. Investors face the trade-off between defensive positioning and potential capital depreciation if the bond rout continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →
